{"id":"NCT00152971","sponsor":"Boehringer Ingelheim","briefTitle":"Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement","officialTitle":"A Phase III, Randomized, Parallel-group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day 1 Followed by 150 mg Day 2-completion, and 110 mg Day 1 Followed by 220 mg Day 2-completion) of Dabigatran Etexilate Administered Orally (Capsules), Compared to Enoxaparin 30 mg Twice a Day Subcutaneous for 12 - 15 Days in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Knee Replacement Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-11","primaryCompletion":"2006-06","completion":null,"firstPosted":"2005-09-12","resultsPosted":"2010-12-17","lastUpdate":"2014-05-05"},"enrollment":2615,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Arthroplasty, Replacement, Knee","Thromboembolism"],"interventions":[{"type":"DRUG","name":"Dabigatran Dose 1 - day 2 to completion","otherNames":[]},{"type":"DRUG","name":"Dabigatran Dose 1 - day 1","otherNames":[]},{"type":"DRUG","name":"Dabigatran Dose 2 - day 2 to completion","otherNames":[]},{"type":"DRUG","name":"Dabigatran Dose 2 - day 1","otherNames":[]},{"type":"DRUG","name":"Enoxaparin","otherNames":[]}],"arms":[{"label":"Dabigatran Dose 1","type":"EXPERIMENTAL"},{"label":"Dabigatran Dose 2","type":"EXPERIMENTAL"},{"label":"Enoxaparin","type":"ACTIVE_COMPARATOR"}],"summary":"To determine the comparative efficacy and safety of two different doses (75mg day 1 followed by 150 mg day 2-completion, and 110 mg day 1 followed by 220 mg day 2-completion) of dabigatran administered orally (capsules), compared to enoxaparin 30 mg twice a day subcutaneous, in prevention of venous thromboembolism in patients with primary elective total knee replacement surgery","primaryOutcome":{"measure":"Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period","timeFrame":"First administration until 12-15 days","effectByArm":[{"arm":"Dabigatran 220mg","deltaMin":188,"sd":null},{"arm":"Dabigatran 150mg","deltaMin":219,"sd":null},{"arm":"Enoxaparin","deltaMin":163,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0234"},{"comp":"OG001 vs OG002","p":"0.0009"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":94,"countries":["United States","Canada","Mexico","United Kingdom"]},"refs":{"pmids":["22709460"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":59,"n":857},"commonTop":["Oedema peripheral","Constipation","Nausea","Pyrexia","Insomnia"]}}